PATH vs RANI
Uipath Inc (PATH) versus Rani Therapeutics Holdings Inc (RANI) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Rani Therapeutics Holdings Inc (RANI) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported RANI revenue for 2024-12-31 was $1.0M. Net income was -$56.6M. RANI currently screens at market cap $41.5M.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. RANI currently screens at market cap $41.5M.
Not investment advice. Open the PATH and RANI stock pages for the full models.
Not investment advice.